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Different lines of evidence indicate that both aberrant activa-
tion of the phosphatidylinositol 3-OH kinase (PI3K)/Akt sur-
vival pathway and down-regulation of the death mediator cera-
mide play a critical role in the aggressive behavior, apoptosis
resistance, and adverse clinical outcome of glioblastoma multi-
forme. Furthermore, the inhibition of the PI3K/Akt pathway
and the up-regulation of ceramide have been found functional
to the activity of many cytotoxic treatments against glioma cell
lines and glioblastomas as well. A reciprocal control between
PI3K/Akt and ceramide signaling in gliomacell survival/death is
suggested by data demonstrating a protective role of PI3K/Akt
on ceramide-induced cell death in glial cells. In this study we
investigated the role of the PI3K/Akt pathway in the regulation
of the ceramide metabolism in C6 glioma cells, a cell line in
which the PI3K/Akt pathway is constitutively activated. Meta-
bolic experiments performed with different radioactive meta-
bolic precursors of sphingolipids and microscopy studies with
fluorescent ceramides demonstrated that the chemical inhibi-
tion of PI3K and the transfection with a dominant negative Akt
strongly inhibited ceramide utilization for the biosynthesis of
complex sphingolipids by controlling the endoplasmic reticu-
lum (ER) to Golgi vesicular transport of ceramide. These find-
ings constitute the first evidence for a PI3K/Akt-dependent reg-
ulation of vesicle-mediated movements of ceramide in the
ER-Golgi district. Moreover, the findings also suggest the acti-
vation of the PI3K/Akt pathway as crucial to coordinate the bio-
synthesis of membrane complex sphingolipids with cell prolif-
eration and growth and/or to maintain low ceramide levels,
especially as concerns those treatments that promote ceramide
biosynthesis in the ER.
Gliomas are themost frequent brain tumors derived from the
transformation of glial cells or their precursors (1–3). The
World Health Organization classifies gliomas according to
their cellular features and their grade of malignancy (from I to
IV) (4). Glioblastoma multiforme (GBM),3 also referred to as
grade IV astrocytoma, is the most frequent class of malignant
primary brain tumor and one of the most aggressive forms of
cancer. There is a poor prognosis for patients with GBM, the
median survival being 9–12 months, and this does not signifi-
cantly improve even after aggressive treatment with multiple
approaches, including surgery, chemotherapy, and radiother-
apy (5). This poor survival rate seems to be mainly due to the
marked invasiveness and proliferation of GBM, as well as to
their apoptotic resistance and aberrant angiogenesis. These
malignancy features could be related to the varying mutations
frequently found in GBM tumors that impact different key
pathways involved in the control of cell proliferation, survival,
differentiation, migration, and DNA repair (6–9).
Among the disregulated signaling pathways in GBMs, PI3K-
Akt-PTENhas been identified as being an important oncogenic
pathway (10–12). PI3Ks are members of a unique and con-
served family of lipid kinases that phosphorylate the 3-hy-
droxyl group of phosphatidylinositol and phosphoinositides
such as phosphatidylinositol(4,5)P2 (PIP2), which is converted
to phosphatidylinositol(3,4,5)P3 (PIP3). The activation of PI3Ks
can occur through growth factor receptors, G-protein-coupled
receptors, cell adhesion molecules, and oncogenes such as Ras.
The generated polyphosphoinositides bind to the pleckstrin
homology (PH) domain of different proteins, including PDK1
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(3-phosphoinositide-dependent protein kinase 1) and the ser-
ine/threonine kinase Akt, thus facilitating the interaction
between the two proteins and the activation of Akt by PDK1.
Cell levels of phosphoinositides are controlled not only by PI3K
but also by the tumor suppressor PTEN. which is a PIP3 phos-
phatase. PTEN negatively regulates the PI3K/Akt pathway by
converting PIP3 back to PIP2. The activation of Akt promotes
cell growth and survival and inhibition of apoptosis and also
regulates glucose and lipid metabolism at both the transcrip-
tional and post-transcriptional levels; furthermore, Akt acti-
vation can exert some control over cell movement and vesicle
trafficking within cells (13). The overexpression or the muta-
tion of PI3K-related genes and the deletion or mutation of
PTEN have been reported in many GBMs and glioblastoma-
derived cell lines (12, 14, 15, 17, 18). Indeed, all the above-
mentioned conditions determine high basal levels of PIPs and
Akt activation, even in the absence of growth factor stimula-
tion. InGBMs, reduced levels of PTEN and increasedAkt activ-
ity have been correlated with more aggressive tumor behavior
and reduced survival time in patients (19,20). The aberrant acti-
vation of PI3K-Akt-PTEN signaling has been identified as cru-
cial to the malignant features of GBMs, such as rapid tumor
growth, invasiveness, resistance to cytotoxic treatments, and
massive neovascularization (12, 22–24).
Ceramide (Cer) has long been recognized as a ubiquitous
mediator of cell death. Indeed, in GBMs, the possibility of dis-
regulation in Cer-dependent signaling is strongly supported by
the evidence of an inverse association between Cer levels and
GBM malignancy progression, and the direct correlation of
such levels with patient survival (25). Moreover, Cer up-regu-
lation has been demonstrated as being crucial to many cyto-
toxic treatments of glioma cells (26–30), and exogenous Cer
has been shown to induce glioma cell death by apoptosis, auto-
phagic cell death, and necrosis (31–33). Cer-induced cell death,
both apoptotic and non apoptotic, can be inhibited by an active
Akt pathway (31, 34). Metabolic pathways involved in control-
ling Cer levels in glial cells include sphingomyelinases, other
specific Cer metabolism enzymes such as serine palmitoyl-
transferase and sphingomyelin synthase, and Cer transport
from the ER to the Golgi apparatus for the biosynthesis of com-
plex sphingolipids (35–41). In addition, it has been demon-
strated that the accumulation of de novo synthesized Cer is an
early event in cannabinoid-triggered ER stress and apoptosis in
glioma cells (40). This suggests that the modulation of Cer lev-
els in the ER/Golgi compartment can be crucial to glioma cell
decision toward survival or death.This study investigates the role
of the PI3K-Akt-PTEN pathway in the regulation of the Cer
metabolism in C6 glioma cells; this is a cell line in which the
PI3K/Akt pathway is constitutively activated due to the lack of
PTEN expression (42). We show that the PI3K/Akt pathway is
capable of regulating the Cermetabolism and its levels in ER by
promoting the biosynthesis of complex sphingolipids acting on
the vesicular ER to Golgi transport of Cer.
EXPERIMENTAL PROCEDURES
Materials—All reagents were of analytical grade as follows:
Dulbecco’s modified Eagle’s medium (DMEM), wortmannin
(Wm), brefeldin A (BFA), bovine serum albumin (BSA), fatty
acid-free BSA, andG418 were purchased from Sigma. Fetal calf
serum (FCS) was fromCambrex (Walkersville,MD). LY294002
and LY303511 were from Cayman Chemical (Ann Arbor, MI).
The antibodies recognizing phospho-Akt (Ser-473) were from
Cell SignalingTechnology, Inc. (Danvers,MA); polyclonal anti-
bodies against Cer transfer protein (CERT) were from Bethyl
Laboratories (Montgomery, TX). Lipofectamine 2000 and the
Stealth RNAi were from Invitrogen. Complete Mini Protease
inhibitor mixture tablets were from Roche Diagnostics.
D-Erythro-[3-3H]sphingosine ([3H]Sph) (21.2 Ci/mmol) and
[choline-methyl-14C]sphingomyelin ([14C]SM) (52 mCi/mmol)
were from PerkinElmer Life Sciences; N-[hexanoyl-6-3H]D-
erythro-hexanoylsphingosine ([3H]C6-Cer) (60 Ci/mmol) was
from ARC (St. Louis, MO). High performance thin layer chro-
matography (HPTLC) silica gel plates were fromMerck. 6-((N-
(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl) sphingo-
sine (NBD-C6-Cer) and BODIPY-C5-Cer were from
Invitrogen. The plasmid encoding the dominant negative form
of Akt (Thr-308 and Ser-473 mutated to Ala) was kindly pro-
vided by Prof. StefanieDimmeler, Department of InternalMed-
icine III, University of Frankfurt, Frankfurt, Germany. The plas-
mid encoding for the PH domain of four phosphate adaptor
protein 1 (FAPP1) fused with enhanced green fluorescent pro-
tein (EGFP-FAPP1-PH) was kindly provided by Dr. Maria
Antonietta DeMatteis, Department of Cell Biology andOncol-
ogy, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti,
Italy.
Cell Culture—The C6 glioma cell line was obtained from the
Istituto Zooprofilattico Sperimentale della Lombardia e
dell’Emilia (Brescia, Italy). Cells were routinely maintained in
DMEM supplemented with 10% FCS, 100 units/ml penicillin,
and 100 g/ml streptomycin at 37 °C in an atmosphere of 5%
CO2 and 95% humidified air.
Plasmids and Transfection—C6 glioma cells were plated in
60-mm cell culture dishes and grown in DMEM supplemented
with 10% FCS until they were 50–70% confluent. Then cells
were transfected with expression plasmid encoding the domi-
nant negative mutant of Akt (DN-AKT) or pcDNA3.1 empty
vector using the Lipofectamine 2000 reagent according to the
manufacturer’s directions. Stable transfectants for DN-AKT
and vector were selected in a 2–3-week period usingG418 anti-
biotic (0.5 g/liter).
PHDomain Binding Assay—C6 glioma cells plated on cover-
slips at 1.5  104 cell/cm2 were grown for 24 h in DMEM plus
10% FCS. Cells were transfected with 4 g of plasmid encoding
for the EGFP-FAPP1-PH domain using Lipofectamine 2000
reagent in accordance with the manufacturer’s protocol. After
24 h the cells were treated for 1.5 h with or without 0.5 MWm
or 5 M Wm or 20 M LY294002 at 37 °C. The cells were then
washed (three times with PBS) and fixed with 0.5% glutaralde-
hyde solution in PBS for 10 min at 4 °C. The specimens were
observed and analyzed with a fluorescence microscope (Olym-
pus BX-50) equipped with a fast high resolution charge-cou-
pled device camera (Colorview 12) and an image analytical soft-
ware (analysis from Soft Imaging System GmbH).
RNA Interference—Small interfering RNA (siRNA) duplexes
for rat CERT (GenBankTM accession number XM 345143.1)
S87, S522, and control nontargeting siRNAs (scrambled
Regulation of Ceramide Vesicular Traffic by PI3K/Akt
FEBRUARY 20, 2009 • VOLUME 284 • NUMBER 8 JOURNAL OF BIOLOGICAL CHEMISTRY 5089
 at U











sequences of S87 and S522 oligonucleotides) described in Ref.
43 were used. C6 glioma cells plated at 3  104 cell/cm2 were
maintained 24 h in DMEM plus 10% FCS and then transfected
in the same medium with a 1:1 (by mol) mix of S87  S522
(si-CERT) or the nontargeting corresponding sequences (si-
control) using Lipofectamine 2000 according to the manufac-
turer’s protocol. All the experiments were performed 72 h after
transfection.
Immunoblotting—Phospho-Akt immunoblotting were per-
formed using C6 glioma cells lysed with Akt buffer (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 10 mM
sodium fluoride, 1 mM EDTA, 10 mMNa4P2O7, 1 mM Na3VO4,
and the protease inhibitor mixture). Solubilized proteins were
centrifuged at 14,000  g at 4 °C for 10 min. Supernatants were
subjected to 10% SDS-PAGE and transferred to nitrocellulose
membranes. Membranes were blocked for 1 h at room temper-
ature in Tris-buffered saline (10 mM Tris-HCl, pH 7.4, 140 mM
NaCl) containing 0.1% Tween 20 (TBS-T) and 5% skim milk,
and then incubated with primary antibodies against phospho-
Akt overnight at 4 °C. Membranes were washed in TBS-T, and
bound antibodies were visualized with horseradish peroxidase-
coupled secondary antibodies (Santa Cruz Biotechnology) and
chemiluminescent substrate. The relative intensities of bands
were quantified by densitometry. CERT immunoblotting was
performed using si-control and si-CERT transfected cells lysed
with CERT buffer (10 mM Tris-HCl, pH 7.4, 0.25 mM sucrose,
0.5 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 5
g/ml leupeptin, 5 g/ml pepstatin), processed, and analyzed
as described previously (43).
[3H]Sphingosine and N-[3H]Hexanoyl-sphingosine Meta-
bolism—C6 glioma cells plated at 1.5  104 cell/cm2 were
grown 48 h in DMEM plus 10% FCS. Cells, preincubated for 30
min with 0.5 MWm, 20 M LY294002, or 20 M LY303511, in
the presence or absence of 1 g/ml BFA, were pulsed with
[3H]Sph (0.3 Ci/ml) or [3H]C6-Cer (0.6 Ci/ml) for 30 min or
1 h maintaining the pretreatment conditions. si-control and
si-CERT cells, preincubated for 30 min with 0.5 M Wm or 20
M LY294002, were pulsed with [3H]Sph (0.3 Ci/ml) for 1 h
maintaining the pretreatment conditions. Stable transfectants
for DN-AKT and vector were pulsedwith [3H]Sph (0.3Ci/ml)
for 1 h. All experiments were performed at 37 °C. Stock solu-
tions of [3H]Sph or [3H]C6-Cer in absolute ethanol were pre-
pared and added to fresh medium. In all cases the final concen-
tration of ethanol never exceeded 0.1% (v/v). At the end of
pulse, cells were washed twice with PBS at 4 °C, harvested, and
submitted to lipid extraction and partitioning as described pre-
viously (44). The methanolized organic phase and the aqueous
phase were analyzed by HPTLC using chloroform/methanol/
water (55:20:3 by volume) and butanol/acetic acid/water (3:1:1
by volume) as solvent system, respectively. Digital autoradiog-
raphy of HPTLC plates was performed with Beta-Imager 2000
(Biospace, France), and the radioactivity associated with indi-
vidual lipidswasmeasured using the software providedwith the
instrument. The 3H-labeled sphingolipids were recognized and
identified as described previously (44).
In Vitro Enzyme Assays—Sphingomyelin synthase (SMS),
glucosylceramide synthase (GCS), and sphingomyelinase
(SMase) activities were assayed using as enzyme source a
homogenate of the control (untreated cells), 0.5MWm-, or 20
M LY294002-treated cells. SMS activity was assayed as
described previously (41), with minor modifications. The incu-
bation mixture contained 50 mM Tris-Cl, pH 7.4, 25 mM KCl,
0.5mMEDTA, 2 nmol (0.05Ci) of [3H]C6-Cer (as 1:1 complex
with fatty acid-free BSA), and 20 g of cell protein in a final
volume of 50 l. After 15 min of incubation at 37 °C, the reac-
tion was stopped by adding 150 l of chloroform/methanol
(1:2, by volume) at 4 °C. GCS activity was assayed as described
previously (41) with minor modifications. The incubation mix-
ture contained 50 mM Tris-Cl, pH 7.4, 25 mM KCl, 10 mM
MnCl2, 5mMUDP-Glc, 2 nmol (0.05Ci) of [3H]C6-Cer (as 1:1
complex with fatty acid-free BSA), and 15g of cell protein in a
final volume of 50 l. After 15 min of incubation at 37 °C, the
reactionwas stopped by adding 150l of chloroform/methanol
(1:2, by volume) at 4 °C. In all cases, after lipid extraction and
phase separation, the [3H]lipids were resolved by HPTLC as
described previously (41). Mg2-dependent neutral SMase
(N-SMase) and acidic SMase (A-SMase) were assayed accord-
ing to Ref. 41 with minor modifications. The N-SMase incuba-
tion mixture contained 20 mM Tris-Cl, pH 7.4, 10 mM MgCl2,
0.1% Triton X-100, 250 M [14C]SM (0.1 Ci), and 5–20 g of
cell protein in a final volume of 25 l. The A-SMase incubation
mixture contained 200 mM acetate buffer (pH 5.0), 10 mM
EDTA, 0.1%TritonX-100, 250M [14C]SM (0.1Ci), and 2–10
g of cell protein in a final volume of 25 l. After 30 min of
incubation at 37 °C, the reactions were stopped by adding 100
l of chloroform/methanol (2:1, by volume) at 4 °C; the radio-
activity associated with the aqueous phase represented by
[14C]phosphocholine was measured.
Analysis of the Intracellular Distribution of Fluorescent
Ceramides—C6 glioma cells or stable transfectants for
DN-AKT and vector were plated at 1.5  104 cells/cm2 and
grownon a glass coverslip for 48 h inDMEMplus 10%FCS. The
cells were then loaded with 5 M BODIPY-C5-Cer or NBD-C6-
Cer (1:1 complex with fatty acid free BSA) as described previ-
ously (43). After loading, the cells were incubated 30 min at
37 °C inDMEMplus 10%FCSwith orwithout 0.5MWmor 20
M LY294002 or 20 M LY303511. The cells were then washed
(three timeswith PBS) and fixedwith 0.5% glutaraldehyde solu-
tion in PBS for 10min at 4 °C. The specimenswere immediately
observed and analyzed with a fluorescence microscope (Olym-
pus BX-50), as described above.
Other Methods—Total protein amount was assayed with the
Coomassie Blue- based reagent (Pierce), using BSA fraction V
as standard. Radioactivity was measured by liquid scintillation
counting. Statistical significance of differences was determined
by the Student’s t test.
RESULTS
Effect of PI3K/Akt on [3H]Sph Metabolism—To investigate
the effect of PI3K/Akt onCermetabolism inC6 glioma cells, we
first utilized the chemical inhibition of PI3K. As the commonly
used PI3K inhibitors Wm and LY294002 can also inhibit type
III PI4Ks, although at higher doses (45), and it has been shown
that PI4KIII plays a role in CERT-mediated Cer metabolism
(46), we initially set up working concentrations to specifically
inhibit PI3K. To do this we evaluated the effect of different
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concentrations ofWmand LY294002 on PI4K activity by stain-
ing cells with the EGFP-FAPP1-PH domain, which specifically
interacts with phosphatidylinositol 4-phosphate (PI4P) (47). As
shown in Fig. 1, the EGFP-FAPP1-PH domain in the control
cells is almost exclusively present in the perinuclear region,
representative of the Golgi complex, supporting the preferen-
tial localization of PI4P in this subcellular compartment (48).
When C6 glioma cells expressing EGFP-FAPP1-PH domain
were treated with 0.5MWmorwith 20MLY294002,most of
the fluorescence accumulated in the Golgi region, thus indicat-
ing that the amount of PI4P in the Golgi complex was
unchanged. Instead, for the cells treated with 5 MWm, which
inhibits type III PI4Ks, there was almost the complete loss of
association between the EGFP-FAPP1-PH domain and the
Golgi complex (Fig. 1). Thus, in subsequent experiments, we
used both 0.5 M Wm and 20 M LY294002 to specifically
inhibit PI3K and evaluated their capacity to block the PI3K/Akt
pathway. Immunoblot analyses with an antibody specific for
Akt, phosphorylated at Ser-473, demonstrated that Wm and
LY294002 strongly reduce Akt activation, because phospho-
Akt is fairly detectable with both treatments (Fig. 2A). On the
contrary, there was no change in the phospho-Akt levels when
the cells were incubated with the LY294002-inactive analogue
LY303511. Subsequently, we performed a metabolic study
using [3H]Sph, a sphingolipid precursor that is efficiently taken
up by glial cells and rapidly incorporated first in Cer and then in
sphingomyelin (SM) and glycosphingolipids (41).WhenC6 gli-
oma cells were pulsed with [3H]Sph in the presence or absence
ofWm, LY294002, or LY303511, the radioactive precursor was
rapidly and efficiently incorporated in both control and treated
cells, and none of the treatments altered the [3H]Sph uptake,
determined as the radioactivity measured in the total lipid
extract (data not shown). In all cases, [3H]Sph was mainly
metabolized to N-acylated compounds, most represented
by [3H]Cer, [3H]SM, and, in lower amounts, [3H]glucosylcera-
mide ([3H]GlcCer) and [3H]GM3 (Fig. 2B). The extent ofN-ac-
ylation (evaluated as the sum of tritiated Cer, SM, GlcCer, and
GM3) was always very similar in the control and treated cells.
However, treatmentwithWmandLY294002 stronglymodified
the radioactivity distribution among the different Sph metabo-
lites. In the Wm- and LY294002-treated cells, [3H]Cer was
higher than in the control cells, with a concomitant reduction
of both [3H]SM and [3H]GlcCer  [3H]GM3 (Fig. 2B) giving
rise to a [3H]SM/[3H]Cer of 1.6, 0.42, and 0.66 and [3H]GlcCer/
[3H]Cer ratios of 0.44, 0.14, and 0.20 in the controls, and the
Wm- and LY294002-treated cells, respectively. Instead, treat-
ing the cells with LY303511 did not have any effect on the
radioactivity distribution among the different N-acyl deriv-
atives of [3H]Sph (Fig. 2B). We then evaluated whether or
not DN-Akt had effects on Cer metabolism similar to the
chemical inhibition of PI3K. When cells expressed the DN-
Akt, the radioactivity distribution among the different
N-acyl derivatives of [3H]Sph was also significantly different
from that of the vector-expressing cells (Fig. 3). In particular,
DN-Akt transfection promoted an increase in [3H]Cer that
was associated with the reduction of both [3H]SM and
[3H]GlcCer, resulting in a [3H]SM/[3H]Cer ratio of 1.6 and
FIGURE 1. Localization of EGFP-FAPP1-PH domain in C6 glioma cells. Cells
were plated at 3.0  104 cells/cm2 on coverslips and grown for 24 h in DMEM
plus 10% FCS. The cells were then transfected with a plasmid encoding the
EGFP-FAPP1-PH domain as described under “Experimental Procedures.” After
24 h, the cells were treated for 1 h in the presence or absence (Control) of 20
M LY294002, or 0.5 M Wm, or 5 M Wm. Then the cells were fixed and
processed for immunofluorescence microscopy (see “Experimental Proce-
dures”). All images were processed and printed identically.
FIGURE 2. Effect of PI3K inhibitors on AKT phosphorylation and [3H]Sph
metabolism in C6 glioma cells. Cells were plated at 1.5  104 cells/cm2 and
grown for 72 h in DMEM plus 10% FCS and pretreated for 30 min with the
different inhibitors. The cells were treated for 1 h with or without (control) 0.5
M Wm, or 20 M LY294002, or 20 M LY303511 and harvested for immuno-
blot analysis of phospho-AKT levels (A), or pulsed 1 h with [3H]Sph in the
absence (closed bars) or presence of 0.5 M Wm (striped bars), 20 M LY294002
(dotted bars), or 20 M LY303511 (thin hatched bar) (B). At the end of pulse,
cells were harvested and submitted to lipid extraction. The [3H]sphingolipid
metabolites associated with the organic and aqueous phase (see “Experimen-
tal Procedures”) were separated by HPTLC. Single lipids were identified by
co-migration with pure standards and quantified by radiodensitometric anal-
ysis. All values are the mean  S.D. of at least three individual experiments.
*, p  0.01 versus control.
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0.79 and a [3H]GlcCer/[3H]Cer ratio of 0.45 and 0.22 in vec-
tor and DN-Akt-transfected cells, respectively. Also in this
case we observed no differences in the uptake and the
amount of N-acylated derivatives in vector- and DN-Akt-
expressing cells (data not shown). Taken together, these
results suggest that the PI3K/Akt pathway can regulate the
metabolic utilization of Cer, favoring themaintenance of low
Cer levels in C6 glioma cells.
Effect of PI3K/Akt on Sphingomyelin Synthase and Glucosyl-
ceramide Synthase Activity in C6GliomaCells—On the basis of
these results, we investigated the possibility that the PI3K/Akt
pathway can positively regulate the biosynthesis of complex
sphingolipids. For this purpose we first evaluated the effect of
Wm and LY294002 on the in vitro enzyme activity of SMS and
GCS. Using the homogenate from control cells, the measured
SMS activity was 0.24 0.04 nmol, mg of protein1 min1 and
that of GCS 0.25  0.03 nmol, mg of protein1 min1. No
differences were observed in either SMS or GCS activities add-
ing Wm or LY294002 to the enzyme assay or using the homo-
genate from Wm- and LY294002-treated cells as enzyme
sources.We then evaluated the effect ofWm and LY294002 on
the metabolic process of [3H]C6-Cer, a short chain, free diffus-
ible analogue of Cer that allows the evaluation of the activity of
SMS and GCS in living cells. Compared with the control cells,
there was no modification of the uptake of [3H]C6-Cer in C6
glioma cells treatedwithWmand LY294002. As shown in Fig. 4
when C6 glioma cells were pulsed for 1 h with [3H]C6-Cer, the
amounts of synthesized [3H]C6-SM and [3H]C6-GlcCer were
very similar in both control and treated cells, thus indicating
that the PI3K/Akt pathway does not affect the activity of these
enzymes in living cells. Taken together, these results indicate
that the reduced utilization of Cer cannot be ascribed to a direct
effect of PI3K/Akt on SMS and GCS. In addition, these results
also indicate that PI3K/Akt inactivation did not influence the
availability of phosphatidylcholine as a substrate for SMS.
Effect of PI3K/Akt onSMaseActivity—Toexclude any contribu-
tion of SM degradation to the increased [3H]SM/[3H]Cer ratio
observed after PI3K/Akt inhibition, we investigated the effects of
Wm and LY294002 on the activity of N-SMase and A-SMase.
Using homogenates obtained from control cells and Wm- or
LY294002-treated cells as enzyme source and adding Wm or
LY294002 to the homogenate of control cells, no differences were
observed in N-SMase or A-SMase activity (data not shown). This
indicates that in C6 glioma cells, contrary towhat was observed in
oligodendrocytes (49), PI3K/Akt did not affect A-SMase activity.
Effect of PI3K/Akt on the Intracellular Distribution of
BODIPY-C5-Cer and NBD-C6-Cer—To clarify the mechanism
responsible for [3H]Cer accumulation consequent to PI3K/Akt
inhibition, we tested the possibility that the inhibition of this
pathway affects the ER to Golgi transport of Cer. The transport
of natural Cer from ER to the Golgi apparatus can be qualita-
tively evaluated from the analysis of BODIPY-C5-Cer redistri-
bution in cells (41, 50, 51); thuswe first investigated the effect of
0.5 M Wm, 20 M LY294002, and 20 M LY303511 on the
distribution of BODIPY-C5-Cer (Fig. 5A). After labeling the ER
and other intracellular membranes, cells were chased in the
presence or absence ofWm, LY294002, or its inactive analogue
LY303511 to allow the redistribution of BODIPY-C5-Cer. In
the control and LY303511-treated cells, most of the fluores-
cence accumulated in the perinuclear region (Fig. 5A)
representative of the Golgi apparatus (50), whereas in the
Wm- and LY294002-treated cells, the accumulation of fluo-
rescence in the Golgi region was strongly reduced (Fig. 5A).
We then evaluated whether or not DN-Akt had similar
effects on Cer traffic as the chemical inhibition of PI3K.
When the cells expressed DN-Akt, the accumulation of flu-
orescence in the Golgi region was also strongly reduced (Fig.
5A). In contrast, the labeling of Wm- and LY294002-treated
and DN-Akt-transfected cells with NBD-C6-Cer (Fig. 5B), a
specific marker of the Golgi complex, demonstrated that
those treatments did not modify the accumulation of NBD
fluorescence in the perinuclear region (Fig. 5B), thus allow-
ing us to exclude the possibility that PI3K inhibition affects
the organization of the Golgi apparatus. Taken together,
these results strongly support the PI3K/Akt pathway regula-
tion of Cer delivery to the Golgi apparatus.
FIGURE 3. Effect of DN-Akt expression on [3H]Sph metabolism in C6 gli-
oma cells. Cells stably transfected with DN-Akt (dotted bars) or empty vector
(closed bars) were plated at 1.5  104 cells/cm2 and grown for 72 h in DMEM
plus 10% FCS. Then cells were pulsed for 1 h with [3H]Sph, harvested, and
analyzed as described in Fig. 2. All values are the mean  S.D. of at least three
individual experiments. *, p  0.01 versus control. FIGURE 4. Effect of PI3K/Akt inhibition on [3H]SM synthase and [3H]Gl-
cCer synthase in C6 glioma cells. Cells plated at 1.5  104 cells/cm2 were
grown for 72 h in DMEM plus 10% FCS and 30 min pretreated with the differ-
ent inhibitors. Then cells were pulse for 1 h with [3H]C6-Cer in the absence
(closed bars) or presence of 0.5 M Wm (striped bars), or 20 M LY294002
(dotted bars). At the end of pulse, cells were harvested and submitted to lipid
extraction. The [3H]C6-Cer metabolites, associated with the organic phase,
were separated and analyzed as described in Fig. 2. All values are the mean 
S.D. of at least three individual experiments.
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Effect of Wm and LY294002 on SM and GlcCer Formation
from [3H]Sph in BFA-treated Cells—Toobtain further evidence
for the effect PI3K/Akt inhibitors onCer traffic, we investigated
the effect of Wm and LY294002 on [3H]Sph metabolism in C6
glioma cells treated with BFA, which leads to the fusion of the
cis-Golgimembranes with the ER (52). Ourworking hypothesis
was that, if Wm and LY294002 determine a defect in ER to the
Golgi apparatus trafficking of Cer, treatment with BFA should
make Cer metabolism insensitive to those inhibitors. Cells pre-
treated with BFA were pulsed 30 min with [3H]Sph in the pres-
ence of BFA alone or withWm or LY294002. Then the conver-
sion of [3H]Cer to [3H]SM and [3H]GlcCer was compared in
control and BFA-treated cells (Fig. 6). In the BFA-treated cells,
the amount of [3H]SM and [3H]GlcCer synthesized from
[3H]Cer was found to be about 87% higher than in the controls.
In the presence of BFA,Wmand LY294002were no longer able
to impair [3H]Cer metabolic utilization, thus implying that
PI3K/Akt inhibitors affect the translocation of Cer from the ER
to the Golgi apparatus.
Effect of PI3K/Akt on [3H]SphMetabolism inC6GliomaCells
Down-regulated for CERT—Recent results obtained in our lab-
oratories indicate that in C6 glioma cells, the ER to Golgi Cer
transport, needed for Cer utilization in complex sphingolipid
biosynthesis, involves both the Cer-binding protein CERT and
a vesicle-mediated mechanism that can separately contribute
to the control of sphingolipid metabolism and Cer levels in
these cells, CERT being specific for SMbiosynthesis (43). Based
on our results that indicate a decrease of both [3H]SM and
[3H]GlcCer after PI3K/Akt inhibition, and taking into account
recent evidence that indicates a role for PI3K/Akt in the regu-
lation of the ER to Golgi protein vesicular transport (53), we
hypothesized that PI3K/Akt can also regulate the ER to Golgi
vesicular traffic of Cer. Recently, we demonstrated (43) that the
cells down-regulated for CERT represent a model for evaluat-
ing the contribution of vesicular traffic of Cer from ER to the
Golgi apparatus, and thus we investigated the effect ofWm and
LY294002 on [3H]Sphmetabolism in control and CERT down-
regulated C6 glioma cells. As reported in Fig. 7 (upper panel),
treatmentwithWmand LY294002 induced a significant reduc-
tion in the biosynthesis of SM and GlcCer as it did in wild type
cells. In fact, as shown in Fig. 7 (upper panel), si-control cell
treatment with Wm and LY294002 determined an 83 and 43%
increase in [3H]Cer with a concomitant decrease of both
FIGURE 5. Effect of PI3K/Akt inhibition on BODIPY-C5-Cer and NBD-C6-Cer
intracellular distribution in C6 glioma cells. Control cells and stable trans-
fectant cells for DN-Akt or vector were plated at 1.5  104 cells/cm2 on a
coverslip and grown for 72 h in DMEM plus 10% FCS. Then the cells were
incubated with 5 M BODIPY-C5-Cer (A) or NBD-C6-Cer (B) for 30 min at 4 °C.
Labeled cells were then incubated at 37 °C for 30 min in the absence (Control,
vector, and DN-Akt) or presence of 0.5 M Wm, 20 M LY303511, and 20 M
LY294002, respectively. All images were processed and printed identically.
FIGURE 6. Effect of PI3K/Akt inhibitors on [3H]Sph metabolism in BFA-
treated C6 glioma cells. Cells were plated at 1.5  104 cells/cm2 and grown
for 72 h in DMEM 10% FCS and preincubated for 30 min with 1 g/ml BFA in
presence or absence of the different inhibitors. Then cells were pulsed with
[3H]Sph for 30 min in the absence (closed bars) or presence of 1 g/ml BFA
(cross-hatched bars), 0.5 M Wm (striped bars), or 20 M LY294002 (dotted bars)
in BFA-containing medium. At the end, the cells were harvested and analyzed
as described in Fig. 2. All values are the mean  S.D. of at least three individual
experiments. *, p  0.01 versus control.
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[3H]SM (45 and 26%) and [3H]GlcCer (31 and 17%). As
expected, in theCERT-silenced cells, the conversion of [3H]Cer
to [3H]SM was strongly reduced, as demonstrated by the drop
in the [3H]SM/[3H]Cer ratio from1.95 in si-control cells to 0.87
in si-CERT cells, whereas [3H]Cer utilization for glycosphingo-
lipid biosynthesis was unaffected. In the si-CERT cells, the
effect of PI3K/Akt inhibition on SM biosynthesis was higher
than in si-control cells because, in si-CERT cells, Wm and
LY294002 promoted a 64 and 34% decrease of [3H]SM, respec-
tively. In the same conditions the reduction of [3H]GlcCer (30
and 15%, respectively) was very similar in control and down-
regulated cells (Fig. 7, lower panel). These results strongly sug-
gest the ER to Golgi vesicular transport as the major target of
PI3K/Akt in the regulation of Cer metabolism.
DISCUSSION
Different lines of evidence indicate that both aberrant acti-
vation of the PI3K/Akt survival pathway (19, 20) and down-
regulation of the death mediator Cer (25) play a critical role in
the aggressive behavior, apoptosis resistance, and adverse clin-
ical outcome of GBMs. Furthermore, now included in the ther-
apeutic strategy design against such tumors is the inhibition of
the PI3K/Akt pathway (12, 22, 24) and the up-regulation of Cer
(26–30). Indeed, a reciprocal control between PI3K/Akt and
Cer signaling in glioma cell survival/death is suggested by data
indicating that Cermay induce apoptosis also by inactivation of
the prosurvival kinase Akt (38, 54), possibly through the activa-
tion of a Cer-dependent protein phosphatase, and by data dem-
onstrating a protective role of PI3K/Akt on Cer-induced cell
death in glial cells (31, 34, 55). This led us to wonder whether
the PI3K-Akt-PTEN pathway is able to regulate Cer metabo-
lism; indeed, if such regulation does occur, some insight could
be gained into crucial aspects that could, after further investi-
gations, strongly influence our knowledge of the sensitivity of
glioma cells to Cer-based cytotoxic treatments.
Here we report that in C6 glioma cells the PI3K/Akt pathway
actually regulates Cer metabolism through a positive control of
the vesicular ER to Golgi transport of Cer, which results in
improved biosynthesis of both SMand glycosphingolipids. This
conclusion is supported by several lines of evidence. Pulse
experiments performed with [3H]Sph indicate that PI3K inhi-
bition by both LY294002 and Wm strongly reduces the meta-
bolic utilization of newly synthesizedCer for the biosynthesis of
both SMand glycosphingolipids. The drop in both the [3H]SM/
[3H]Cer and [3H]GlcCer/[3H]Cer ratios, consequent to PI3K
inhibition, was not because of reduced SMS and GCS activity;
in addition, the amount of [3H]C6-SM and [3H]C6-GlcCer syn-
thesized after pulse with [3H]C6-Cer, an experimental condi-
tion allowing an evaluation of the activity of these enzymes in
living cells, was not affected by the LY294002 and Wm treat-
ment. Moreover, treatment of C6 glioma cells with BFA, which
causes Golgi disassembly and redistribution to the ER (52), and
direct Cer availability for SMS andGCS, renders the glioma cell
Cer metabolism insensitive to PI3K inhibitors. It emerges from
these findings that the ER to Golgi transport of Cer is a PI3K
regulated step of sphingolipid biosynthesis. An analysis of
intracellular distribution of BODIPY-C5-Cer, which mimics
the intracellular movements of natural Cer (41, 50, 51), pro-
vides additional evidence that, in C6 glioma cells, PI3K inhibi-
tion strongly limits Cer traffic from ER to the Golgi apparatus
without altering the Golgi apparatus organization, as demon-
strated by data obtainedwithNBD-C6-Cer, a specificmarker of
the Golgi complex (50). Moreover, as demonstrated by both
metabolic and fluorescence microscopy studies, the effect of
PI3K inhibitors on the ER to Golgi Cer traffic was mimicked by
the expression of a dominant negative form of Akt in C6 glioma
cells. Taken together, the data strongly support the involve-
ment of the PI3K/Akt survival pathway in glioma cells in con-
trolling the ER to Golgi Cer traffic. We recently demonstrated
(43) that in C6 glioma cells the ER to Golgi transport of Cer is
operated by the Cer-binding protein CERT, which specifically
acts on SM biosynthetic process, and by a vesicle-mediated
mechanism, functional to Cer utilization for both SM and
GlcCer biosynthesis. Even if the concomitant decrease of both
SM and GlcCer in PI3K/Akt-inhibited cells indicates the vesic-
ular pathway as the most probable target of PI3K/Akt, very
convincing evidence in this regard is given by results obtained
in cells down-regulated for CERT, which represent a good
model to study the vesicular transport of Cer. In fact, when the
protein-mediated transport of Cer is knocked down, the PI3K/
Akt inhibition still promotes a decrease in the biosynthesis of
bothGlcCer and SM, the efficiency of the PI3K/Akt blockade in
inhibiting SM biosynthesis being higher in the control than in
FIGURE 7. Effect of PI3K/Akt inhibitors on [3H]Sph metabolism in C6 gli-
oma cells down-regulated for CERT. Cells plated at 3  104 cell/cm2 were
maintained 24 h in DMEM plus 10% FCS before transfection with siRNA for
CERT (si-CERT) or nontargeting sequences (si-control). After 72 h cells were
pulsed with [3H]Sph for 1 h in the presence or absence (closed bars) of 0.5 M
Wm (striped bars) or 20 M LY294002 (dotted bars). At the end, cells were
harvested and analyzed as described in Fig. 2. All values are the mean  S.D.
of at least three individual experiments. *, p  0.01 versus control; **, p  0.05
versus control.
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the silenced cells, and the combined treatments having an addi-
tive effect on SMbut not onGlcCer biosynthesis. Protein phos-
phorylation, known to modulate many membrane traffic pro-
cesses throughout the cells, has also been implicated in the
transport between the ER and Golgi (53, 56), and different pro-
tein kinases, includingAkt (53), have been shown to regulate ER
to Golgi traffic. To the best of our knowledge, this study is the
first to show that the PI3K/Akt pathway can participate in con-
trolling the sphingolipid metabolism and the regulation of Cer
levels by acting on the vesicle-mediated movements of Cer in
the ER-Golgi district, but the precise target of Akt still remains
undisclosed. Because the activation of PI3K/Akt is downstream
different proliferative/survival signals and the synthesis of new
membrane are absolute requirements for cell growth and pro-
liferation, the connection between PI3K/Akt and the biosyn-
thesis of SM and glycosphingolipids could represent a mecha-
nism to coordinate the production of crucial components of
cell membranewith the proliferative attitude of the cells. In this
context it is interesting to note that the PI3K/Akt pathway can
positively regulate cholesterol biosynthesis by favoring the acti-
vating processing of SCAP/SREBP on its ER to Golgi move-
ments (53). Furthermore, both Cer biosynthesis in the ER (57)
and the biosynthesis of complex sphingolipids have been posi-
tively correlated with the activating processing of SREBP (58,
59), independently of cellular cholesterol concentration. Thus
we can hypothesize a role for the PI3K/Akt pathway to coordi-
nate the metabolism of SM and cholesterol, membrane lipids
known to co-localize in cell membrane lipid rafts. The capacity
of the PI3K/Akt pathway to regulate sphingolipid metabolism
may also be pathologically relevant in gliomas if we consider
that the more malignant phenotypes of these tumors are asso-
ciated with the up-regulation of the PI3K/Akt pathway (19, 20),
increased amounts of SM (60), and low Cer levels (25). More-
over, the SM/Cer mole ratio in PTEN-mutated C6 glioma cells
(43) was significantly higher than in different glioma cell lines
characterized by wild type PTEN (61). This suggests that, in
gliomas, the PI3K/Akt pathway could contribute to Cer down-
regulation by directing it toward SM synthesis, as a means of
avoiding cell growth arrest and cell death. It is also tempting to
speculate that Cer removal, as a consequence of a hyper-acti-
vated PI3K/Akt pathway, could somehow be involved in Cer-
based cytotoxic treatment refractoriness in gliomas, especially
as far as concerns those treatments that, in ER, act through Cer
biosynthesis stimulation (16, 21). Based on recent evidence
showing that PI3K inhibition synergizes with chemotherapy or
death-inducing ligands to trigger apoptosis in glioblastoma
cells (24), our findings could have important implications for
Cer-based glioma therapy, and could provide a basis for further
investigations into the overcoming of cell death resistance in
glioblastomas.
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